Compile Data Set for Download or QSAR
maximum 50k data
Found 64 Enz. Inhib. hit(s) with all data for entry = 50020271
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50212033(4-(4-(2-aminopropan-2-yl)phenyl)-2-(4-(2-(4-methyl...)
Affinity DataIC50:  21nMAssay Description:Inhibition of VEGFR2 activityMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50212029(4-(4-(2-aminopropan-2-yl)phenyl)-2-(4-(2-morpholin...)
Affinity DataIC50:  27nMAssay Description:Inhibition of VEGFR2 activityMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50212040(4-(4-(2-aminopropan-2-yl)phenyl)-2-(4-(2-hydroxyet...)
Affinity DataIC50:  52nMAssay Description:Inhibition of VEGFR2 activityMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50212034(4-(4-(2-aminopropan-2-yl)phenyl)-2-(3-(2-morpholin...)
Affinity DataIC50:  55nMAssay Description:Inhibition of VEGFR2 activityMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50212043(4-phenyl-2-(4-(pyrrolidin-1-ylmethyl)phenylamino)p...)
Affinity DataIC50:  61nMAssay Description:Inhibition of VEGFR2 activityMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50212021(2-(4-(2-hydroxyethyl)phenylamino)-4-(thiophen-2-yl...)
Affinity DataIC50:  82nMAssay Description:Inhibition of VEGFR2 activityMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50212017(2-(4-(2-hydroxyethyl)phenylamino)-4-(1H-indol-5-yl...)
Affinity DataIC50:  90nMAssay Description:Inhibition of VEGFR2 activityMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50212036(2-(3-methoxy-4-(pyrrolidin-1-ylmethyl)phenylamino)...)
Affinity DataIC50:  91nMAssay Description:Inhibition of VEGFR2 activityMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50212014(4-(4-(2-aminopropan-2-yl)phenyl)-2-(4-(2-(2-ethyl-...)
Affinity DataIC50:  94nMAssay Description:Inhibition of VEGFR2 activityMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50212030(4-phenyl-2-(4-(2-(pyrrolidin-1-yl)ethyl)phenylamin...)
Affinity DataIC50:  110nMAssay Description:Inhibition of VEGFR2 activityMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50212016(2-(4-(2-hydroxyethyl)phenylamino)-4-(4-methoxyphen...)
Affinity DataIC50:  150nMAssay Description:Inhibition of VEGFR2 activityMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50212027(4-(4-bromophenyl)-2-(4-(2-hydroxyethyl)phenylamino...)
Affinity DataIC50:  180nMAssay Description:Inhibition of VEGFR2 activityMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50212031(2-(4-(3-morpholino-3-oxopropyl)phenylamino)-4-phen...)
Affinity DataIC50:  180nMAssay Description:Inhibition of VEGFR2 activityMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50212022(4-(5-cyano-2-(4-(2-hydroxyethyl)phenylamino)pyrimi...)
Affinity DataIC50:  200nMAssay Description:Inhibition of VEGFR2 activityMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50212028(2-(4-(2-hydroxyethyl)phenylamino)-4-phenylpyrimidi...)
Affinity DataIC50:  200nMAssay Description:Inhibition of VEGFR2 activityMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50212026(4-(benzo[d]thiazol-2-yl)-2-(4-(2-hydroxyethyl)phen...)
Affinity DataIC50:  340nMAssay Description:Inhibition of VEGFR2 activityMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50212038(2-(3-(morpholinomethyl)phenylamino)-4-phenylpyrimi...)
Affinity DataIC50:  360nMAssay Description:Inhibition of VEGFR2 activityMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50212019(2-(3-methoxyphenylamino)-4-phenylpyrimidine-5-carb...)
Affinity DataIC50:  380nMAssay Description:Inhibition of VEGFR2 activityMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50212013(2-(4-(2-hydroxyethyl)phenylamino)-4-(4-(2-hydroxyp...)
Affinity DataIC50:  410nMAssay Description:Inhibition of VEGFR2 activityMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50212017(2-(4-(2-hydroxyethyl)phenylamino)-4-(1H-indol-5-yl...)
Affinity DataIC50:  410nMAssay Description:Inhibition of CDK1 activityMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50212032(2-(2-methyl-1H-indol-5-ylamino)-4-phenylpyrimidine...)
Affinity DataIC50:  410nMAssay Description:Inhibition of VEGFR2 activityMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50212039(4-(4-(2-aminopropan-2-yl)phenyl)-2-(4-(2-morpholin...)
Affinity DataIC50:  450nMAssay Description:Inhibition of VEGFR2 activityMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50212021(2-(4-(2-hydroxyethyl)phenylamino)-4-(thiophen-2-yl...)
Affinity DataIC50:  470nMAssay Description:Inhibition of CDK1 activityMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50212035(2-(4-methoxyphenylamino)-4-phenylpyrimidine-5-carb...)
Affinity DataIC50:  490nMAssay Description:Inhibition of VEGFR2 activityMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50212026(4-(benzo[d]thiazol-2-yl)-2-(4-(2-hydroxyethyl)phen...)
Affinity DataIC50:  560nMAssay Description:Inhibition of CDK1 activityMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50212041(4-phenyl-2-(phenylamino)pyrimidine-5-carbonitrile ...)
Affinity DataIC50:  1.00E+3nMAssay Description:Inhibition of VEGFR2 activityMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50212023(2-(p-toluidino)-4-phenylpyrimidine-5-carbonitrile ...)
Affinity DataIC50:  1.00E+3nMAssay Description:Inhibition of VEGFR2 activityMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50212024(4-tert-butyl-2-(4-(2-hydroxyethyl)phenylamino)pyri...)
Affinity DataIC50:  1.10E+3nMAssay Description:Inhibition of CDK1 activityMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50212042(2-(4-(2-hydroxyethyl)phenylamino)-4-(1H-indol-2-yl...)
Affinity DataIC50:  1.40E+3nMAssay Description:Inhibition of VEGFR2 activityMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50212016(2-(4-(2-hydroxyethyl)phenylamino)-4-(4-methoxyphen...)
Affinity DataIC50:  1.50E+3nMAssay Description:Inhibition of CDK1 activityMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50212024(4-tert-butyl-2-(4-(2-hydroxyethyl)phenylamino)pyri...)
Affinity DataIC50:  1.60E+3nMAssay Description:Inhibition of VEGFR2 activityMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50212040(4-(4-(2-aminopropan-2-yl)phenyl)-2-(4-(2-hydroxyet...)
Affinity DataIC50:  1.60E+3nMAssay Description:Inhibition of CDK1 activityMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50212042(2-(4-(2-hydroxyethyl)phenylamino)-4-(1H-indol-2-yl...)
Affinity DataIC50:  1.70E+3nMAssay Description:Inhibition of CDK1 activityMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50212022(4-(5-cyano-2-(4-(2-hydroxyethyl)phenylamino)pyrimi...)
Affinity DataIC50:  1.90E+3nMAssay Description:Inhibition of CDK1 activityMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50212027(4-(4-bromophenyl)-2-(4-(2-hydroxyethyl)phenylamino...)
Affinity DataIC50:  2.00E+3nMAssay Description:Inhibition of CDK1 activityMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50212028(2-(4-(2-hydroxyethyl)phenylamino)-4-phenylpyrimidi...)
Affinity DataIC50:  2.00E+3nMAssay Description:Inhibition of CDK1 activityMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50212038(2-(3-(morpholinomethyl)phenylamino)-4-phenylpyrimi...)
Affinity DataIC50:  2.00E+3nMAssay Description:Inhibition of CDK1 activityMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50212015(2-(naphthalen-2-ylamino)-4-phenylpyrimidine-5-carb...)
Affinity DataIC50:  2.10E+3nMAssay Description:Inhibition of VEGFR2 activityMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50212031(2-(4-(3-morpholino-3-oxopropyl)phenylamino)-4-phen...)
Affinity DataIC50:  2.10E+3nMAssay Description:Inhibition of CDK1 activityMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50212013(2-(4-(2-hydroxyethyl)phenylamino)-4-(4-(2-hydroxyp...)
Affinity DataIC50:  2.70E+3nMAssay Description:Inhibition of CDK1 activityMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50212032(2-(2-methyl-1H-indol-5-ylamino)-4-phenylpyrimidine...)
Affinity DataIC50:  3.30E+3nMAssay Description:Inhibition of CDK1 activityMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50212035(2-(4-methoxyphenylamino)-4-phenylpyrimidine-5-carb...)
Affinity DataIC50:  3.30E+3nMAssay Description:Inhibition of CDK1 activityMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50212023(2-(p-toluidino)-4-phenylpyrimidine-5-carbonitrile ...)
Affinity DataIC50:  3.50E+3nMAssay Description:Inhibition of CDK1 activityMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50212029(4-(4-(2-aminopropan-2-yl)phenyl)-2-(4-(2-morpholin...)
Affinity DataIC50:  4.10E+3nMAssay Description:Inhibition of CDK1 activityMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50212019(2-(3-methoxyphenylamino)-4-phenylpyrimidine-5-carb...)
Affinity DataIC50:  4.20E+3nMAssay Description:Inhibition of CDK1 activityMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50212014(4-(4-(2-aminopropan-2-yl)phenyl)-2-(4-(2-(2-ethyl-...)
Affinity DataIC50:  4.80E+3nMAssay Description:Inhibition of CDK1 activityMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50212033(4-(4-(2-aminopropan-2-yl)phenyl)-2-(4-(2-(4-methyl...)
Affinity DataIC50:  5.60E+3nMAssay Description:Inhibition of CDK1 activityMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50212034(4-(4-(2-aminopropan-2-yl)phenyl)-2-(3-(2-morpholin...)
Affinity DataIC50:  5.70E+3nMAssay Description:Inhibition of CDK1 activityMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50212043(4-phenyl-2-(4-(pyrrolidin-1-ylmethyl)phenylamino)p...)
Affinity DataIC50:  6.20E+3nMAssay Description:Inhibition of CDK1 activityMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50212030(4-phenyl-2-(4-(2-(pyrrolidin-1-yl)ethyl)phenylamin...)
Affinity DataIC50:  6.50E+3nMAssay Description:Inhibition of CDK1 activityMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
Displayed 1 to 50 (of 64 total ) | Next | Last >>
Jump to: